1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

Autor:	AB Fernández Román, M García Gil, N Herrero Muñoz, J Letellez Fernández, C Bravo Lázaro, C Mayo López, A Andrés Rosado, Mdm Garcia Gutierrez
Rok vydání:	2018
Předmět:	Oncology medicine.medical_specialty Cost effectiveness business.industry Cost-effectiveness analysis medicine.disease Second line Docetaxel Section 1: Introductory statements and governance Internal medicine Medicine In patient Non small cell Nivolumab business Lung cancer medicine.drug
Zdroj:	Eur J Hosp Pharm
DOI:	10.1136/ejhpharm-2018-eahpconf.5
Popis:	BACKGROUND: Nivolumab (NIV) is a monoclonal antibody for patients with pre-treated advanced nonsquamous non–small-cell lung cancer (NSCLC). It is necessary to evaluate the cost effectiveness of NIV versus docetaxel (DOC), taking into consideration the expression of programmed death ligand 1 (PD-L1). PURPOSE: Cost-effectiveness analysis from the payer’s perspective of NIV versus DOC in patient with nonsquamus NSCLC by expression of PD-L1 test (subgroups
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abc6ce93cb992732d26fd26bf96f60a https://doi.org/10.1136/ejhpharm-2018-eahpconf.5 Zobrazit plný text záznamu